

03-27-2002



102033149

In Re the Application of: )  
 )  
 SAGSTETTER )  
 )  
 Serial No.: 09/521,739 )  
 )  
 Filed: March 9, 2000 )  
 )  
 Atty. File No.: 4414-3 )  
 )  
 For: "DEVICE FOR COLLECTING A )  
 BLOOD SAMPLE FROM A PLASTIC )  
 SEGMENT TUBE" )

AND TRADEMARK OFFICE

Group Art Unit: 1743

Examiner: HANDY, DWAYNE K.

RECORDATION OF ASSIGNMENT

OFFICE OF PUBLIC RECORDS  
 2002 MAR - 5 PM 2:14  
 FINANCE SECTION

"EXPRESS MAIL" MAILING LABEL NUMBER: EL 767781149 US  
 DATE OF DEPOSIT: March 5, 2002

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED  
 WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST  
 OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE  
 INDICATED ABOVE AND IS ADDRESSED TO THE ASSISTANT  
 COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

TYPED OR PRINTED NAME: Angela P. Davis

SIGNATURE:

BOX ASSIGNMENTS  
 Commissioner of Patents  
 Washington, D.C. 20231

Dear Sir:

*3.502*

Please record the attached original documents or copy thereof:

1. Name of conveying party(ies):

Baxter Healthcare Corporation  
 One Baxter Parkway  
 Deerfield, Illinois 60015

2. Name and address of receiving party(ies):

Baxter International Inc.  
 One Baxter Parkway  
 Deerfield, Illinois 60015

3. Nature of Conveyance:

- |                                     |                    |                          |                |
|-------------------------------------|--------------------|--------------------------|----------------|
| <input checked="" type="checkbox"/> | Assignment         | <input type="checkbox"/> | Merger         |
| <input type="checkbox"/>            | Security Agreement | <input type="checkbox"/> | Change of Name |
| <input type="checkbox"/>            | Other: _____       |                          |                |

*09/521739*

Execution Date: October 24, 1973

03/26/2002 TDIAZ1 00000209 09521739  
 01 FC:581 40.00 OP

4. Name and address of party to whom correspondence concerning documents should be mailed:

Douglas W. Swartz  
Sheridan Ross P.C.  
1560 Broadway, Suite 1200  
Denver, Colorado 80202-5141

5. Total number of applications and patents involved:

1.

6. Total fee (37 CFR 3.41).....\$40.00.

Enclosed

Any deficiency in payment of recording fee is authorized to be charged to Deposit Account.

Authorized to be charged to deposit account.

7. Deposit account number: 19-1970.

8. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Total number of pages including cover sheet, attachments and document: 4

Respectfully submitted,

SHERIDAN ROSS P.C.

By: 

Douglas W. Swartz  
Registration No. 37,739  
1560 Broadway, Suite 1200  
Denver, Colorado 80202-5141  
(303) 863-9700

Date: March 5, 2002

M:\4414\3\RecordationConsent.wpd

Excerpted from:

CONSENT AND RECORD OF ACTION OF THE BOARD OF DIRECTORS  
of

TRAVENOL LABORATORIES, INC. [known as Baxter Healthcare  
Corporation since July 21, 1987] a Delaware corporation

October 24, 1973

WHEREAS it is the policy of Baxter Laboratories, Inc., [known as BII (since 5/18/88)], this Corporation's [BHC's] parent, to hold and own all of the patents, trademarks and inventions acquired or made by its [BII's] subsidiaries and to license such intangible assets to its [BII's] subsidiaries pursuant to uniform license agreements; and

WHEREAS, pursuant to said policy, all inventions made and trademarks acquired by this Corporation [BHC] have been deemed to have been distributed to Baxter Laboratories, Inc. [BII] immediately following such making or acquisition and, when warranted, Baxter Laboratories, Inc. [BII] has then proceeded to file and prosecute domestic and foreign patent applications on such inventions and register such trademarks; and

WHEREAS, this Corporation [BHC] now wishes to ratify and confirm the past distributions of such inventions and trademarks and to adopt a policy covering such distributions in the future;

NOW THEREFORE, it is hereby:

RESOLVED, that all past distributions to Baxter Laboratories, Inc. [BII] of inventions made and trademarks acquired by this Corporation [BHC], which distributions have been deemed to have taken place immediately following such making or acquisition, are hereby ratified and confirmed as dividends in kind;

FURTHER RESOLVED, that this Corporation [BHC] hereby adopts a policy of transferring to its parent corporation [BII] as a dividend in kind, all inventions made and trademarks acquired by it [BHC], which distributions shall take place immediately after such making or acquisition and without further corporate action.

January 2, 1980

WHEREAS, it is the policy of Baxter Travenol Laboratories, Inc., [known as BII since 5/18/88] this Corporation's [BHC's] parent, to hold and own all of the patents, trademarks, and inventions acquired or made by its [BII's] subsidiaries; and

WHEREAS, pursuant to said policy, this Corporation [BHC] adopted a resolution on October 24, 1973, providing that all inventions made and trademarks acquired by this Corporation [BHC] be distributed as a dividend in kind to Baxter Travenol Laboratories, Inc. [BII], immediately following such making or acquisition and, when warranted, Baxter Travenol Laboratories, Inc. [BII], has then proceeded to file and prosecute domestic and foreign patent applications on such inventions and register such trademarks; and

WHEREAS, this Corporation [BHC] now wishes to modify the policy concerning distributions of such inventions and trademarks and to adopt a new policy covering such distribution in the future;

NOW, THEREFORE, it is hereby:

RESOLVED, that this Corporation [BHC] hereby adopts a policy of transferring to its parent corporation [BII] as a dividend in kind, all inventions made and trademarks (including goodwill) acquired by it [BHC], on condition that, for so long as the parent corporation [BII] shall hold title to or have the power to grant licenses under such inventions and trademarks, the parent corporation [BII] shall grant to this Corporation [BHC] a royalty-free, worldwide, nonexclusive license under such inventions and trademarks, and patents or registrations resulting therefrom, to practice, manufacture, have manufactured, use, and sell all items covered by such inventions, trademarks, patents and registrations, which dividends shall take place immediately after such making or acquisition and without further corporation action.

PATENT